Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

MOTS-C vs Humanin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

MOTS-C has stronger documented evidence (Early Clinical + Animal Studies) than Humanin (Preclinical + Animal Studies) while both occupy the mdp class. When clinical-evidence tier is the deciding factor, MOTS-C is the safer pick. Humanin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

MOTS-C

Early Clinical + Animal Studies

Humanin

Preclinical + Animal Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

MOTS-C Humanin
Class Mitochondrial-derived peptide (MDP); metabolic regulator Mitochondrial-derived peptide (MDP); cytoprotective
Drug class Metabolic & Weight Longevity
Mechanism Activates AMPK; regulates methionine-folate cycle; insulin sensitization; exercise mimetic Binds BAX and IGFBP3; anti-apoptotic; metabolic regulation
Route SC injection SC (research)
Half-life ~1 hr Unknown
Dosage (research) 5 mg SC 2x weekly (research starting dose, range up to 10 mg 3x weekly per anecdotal vendor protocols) Research dosing varies
Evidence tier Early Clinical + Animal Studies Preclinical + Animal Studies
Research depth 185 indexed (PubMed 155 · CT 1 · EPMC 29) 184 indexed (PubMed 149 · CT 0 · EPMC 35)
Availability Research Research
Reported risks Limited human trials; unknown long-term effects Very limited human data

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick MOTS-C or Humanin?

MOTS-C has stronger documented evidence (Early Clinical + Animal Studies) than Humanin (Preclinical + Animal Studies) while both occupy the mdp class. When clinical-evidence tier is the deciding factor, MOTS-C is the safer pick. Humanin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between MOTS-C and Humanin?

MOTS-C is classed as Mitochondrial-derived peptide (MDP); metabolic regulator; Humanin is classed as Mitochondrial-derived peptide (MDP); cytoprotective. Reported mechanism: MOTS-C, Activates AMPK; regulates methionine-folate cycle; insulin sensitization; exercise mimetic; Humanin, Binds BAX and IGFBP3; anti-apoptotic; metabolic regulation. Reported half-life: MOTS-C, ~1 hr; Humanin, Unknown. Routes in published studies: MOTS-C, SC injection; Humanin, SC (research).

Which has stronger evidence, MOTS-C or Humanin?

MOTS-C has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. MOTS-C is graded Early Clinical + Animal Studies, with 3 cited sources on its reference page and 185 indexed studies. Humanin is graded Preclinical + Animal Studies, with 19 cited sources on its reference page and 184 indexed studies.

Which is more accessible, MOTS-C or Humanin?

Neither MOTS-C nor Humanin is an FDA-approved drug. Catalog status: MOTS-C, Research; Humanin, Research. FDA's Pharmacy Compounding Advisory Committee voted 7 for, 5 against, 2 abstentions on 23 July 2026 to recommend MOTS-C for the 503A Bulks List; the vote is advisory and changes nothing by itself.

Are MOTS-C and Humanin ever combined?

MOTS-C and Humanin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…